0360

Attorney Docket No. 22918/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lucia Irene Gonzalez-Villasenor

Application No.: 10/080,919 Group Art Unit:

FILED: February 22, 2002 Examiner:

FOR: Methods and Composition for Production of Recombinant Peptides

****

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231 on:

By: Michelle A. Phinney June 7, 2002
Michelle A. Phinney Date

****

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE THE MAILING DATE OF A FIRST OFFICE ACTION ON THE MERITS)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

Application No.: 10/080,919
Filed: February 22, 2002
Group Art Unit:

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. __X__ **Submitted herewith is a legible copy of (i) each U.S and foreign patent**; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. __X__ Except as may be indicated below in (b), **all of the patents, publications or other information are in the English language** or were cited in an English language Search Report, a copy of which is attached hereto **(concise explanation not required).**

b. _____ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. _____ The following additional information is provided for the Examiner's consideration:

Application No.: 10/080,919
Filed: February 22, 2002
Group Art Unit:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

a. _____ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. _____ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. __X__ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of $240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):

(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

a. _____ No certification; therefore, a fee in the amount of $240.00 is required by 37 C.F.R. . § 1.17(p).

or

b. __X__ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

a. _____ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

b. _____ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

c. _____ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

_____ Please charge Deposit Account No. 500369 in the amount of $180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

__X__ No fee is required.

Application No.: 10/080,919
Filed: February 22, 2002
Group Art Unit:

VII. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.704(d) (PATENT TERM ADJUSTMENT)

Applies to original applications (other than design) filed on or after May 29, 2000

a. _____ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

b. __X__ Enclosed herewith is form PTO-1449.

c. __X__ Copies of cited references are enclosed.

d. _____ The listed references were cited in the enclosed International Search. Report in a counterpart foreign application.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 500369.

Respectfully submitted,

Date: _____

_____
Thomas M. Saunders, Esq.
Registration No. 29,585
Customer No. 21710
Brown Rudnick Berlack Israels LLP
One Financial Center
Boston, MA 02111
Tel: (617) 856-8284
Fax: (617) 856-8201

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. **22918/1**	SERIAL NO. **10/080,919**
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
		5,523,215	06/04/1996	Cousens et. al.	435	69.1	
		4,677, 196	06/30/1987	Rausch et. al.	530	412	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
		EP 0 433 225 B1	Nov. 27 1990	EPO	C07K	14/495	Y

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1	"Recombinant-DNA-derived bovine growth hormone from *Escherichia coli*", Keith E. Langley et. al., Eur J. Biochem, 163, pp 313-321, (1987)
2	"Plasminogen activator inhibitor-1 fused with erythropoietin (EPO) mimetic peptide (EMP) enhances the EPO activity of EMP", Le-tian Kuai et.al., J. Peptide Res., 56, 2000, pp 59-62
3	"Biopharmaceutical formulation", J. Ching Lee, Current Opinion in Biotechnology, 2000, 11, pp 81-84
4	"Purification and Characterization of Human Interleukin-1 Expressed in *Escherichia Coli*", Shirley R. Kronheim et.al., Bio Technology, Vol. 4, December 1986, pp 1078-1082
5	"Expression, renaturation and purification of recombinant human interleukin 4 from *Escherichia coli*", Anita van Kimmenade et. al., Eur. J. Biochem, pp 109-114 (1988)
6	"Expression of a biologically active fragment of human IgE ε chain in *Escherichia coli*, Fu-Tong Liu et. al., Proc. Natl. Acad. Sci. USA, Vol. 81, pp 5369-5373, September 1984
7	"Renaturation of *Escherichia coli* Tryptophanase after Exposure to 8 M Urea, Evidence for the Existence of Nucleation Centers", Jacqueline London et. al., Eur. J. Biochem. 47, 409-415 (1974)
8	"Inclusion Bodies from Proteins Produced at High Levels in Escherichia coli", Joanna K. Krueger et. al., Amer. Assoc. for the Adv. Science, 1990, pp 136-142
9	"Refolding of Recombinant Proteins", Tadahiko Kohno et. al., Methods in Enzymology, Vol 185, pp 187-195, 1990
10	"*E. coli* expression and characterization of a mutant troponin I with the three cysteine residues substituted", Lan Kluwe et. al., FEBS, Vol 323, number 1.2, pp 83-88, May 1993

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

11	"Production of a biologically active novel goldfish growth hormone in *Escherichia coli*, Soheil S. Mahmoud et. al., Comparative Biochemistry and Physiology, Part B, Vol 120, 1998, pp 657-663
11A	"Intermediates in the Folding Reactions of Small Proteins", Peter S. Kim et. al., Annu. Rev. Biochem, 1990, 59, 631-660
12	"Refolding and Association of Oligomeric Proteins", Rainer Jaenicke et. al., Methods in Enzymology, 1986, 131, pp 218-250
13	"Preparation of Biologically Active Platelet-Derived Growth Type BB from a Fusion Protein Expressed in *Escherichia coli*", J. Hoppe et. al., Biochemistry, 1989, 28, 2956-2960
14	"Pathways of Protein Folding", C. Robert Matthews, Annu. Rev. Biochem. 1993, 62, 653-683
15	"The Purification of eukaryotic polypeptides synthesized in *Escherichia coli*", Fiona A. O. Marston, Biochem. J. (1986), 240, 1-12
16	"Purification of biologically active simian virus 40 small tumor antigen", Ilan Bikel et. al., Proc. Natl. Acad. Sci. USA, Vol. 80, pp 906-910, February 1983
17	"Recombinant Chicken and Bovine Growth Hormones Accelerate Growth in Aquacultured Juvenile Pacific Salmon *Oncorhynchus Kisutch*", Jacqueline, A. Gill et. al, Bio/Technology, Vol 3, July 1985, pp 643-646
18	"Renaturation of Enzymes after Polyacrylamide Gel Electrophoresis in the Presence of Sodium Dodecyl Sulfate", Sanford A. Lacks et. al., The Journal of Biological Chemistry, Vol. 255, No. 15, August 10 1980, pp 7467-7473
19	"Cloning and expression of cDNA for salmon growth hormone in *Escherichia coli*", Susumu Sekine et. al., Proc. Natl. Acad. Sci. USA, Vol. 82, July 1985, pp 4306-4310
20	"Purification of Calf Prochymosin (Prorennin) Synthesized in *Escherichia Coli*, Fiona A.O. Marston et. al., Bio/Technology, September 1984, pp 800-804

Examiner:	**Date:**

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. **22918/1**	SERIAL NO. **10/080,919**
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

21	"Expression and equilibrium denaturation of cardiac troponin I: stabilization of a folding intermediate during denaturation by urea", Nihmat Morjana et al., Biotechnol. Appl. Biochem. (1998), 28, pp 7-17
22	"The Cyanogen Bromide Reaction", Erhard Gross, Cleavage of Peptide Chains, pp 238-263
23	"Gel Electrophoresis and Isoelectric Focusing of Proteins – Selected Techniques", R.C. Allen et. al., 1984
24	"In vitro folding of inclusion body proteins", Rainer Rudolph et. al., The FASEB Journal, January 1996, Vol 10, pp 49-56
25	"Purification and Immunogenicty of Fusion VP1 Protein of Foot and Mount Disease Virus", Steven J. Shire et. al., Biochemistry, 1984, 23, 6474-6480
26	"Examination of calf prochymosin accumulation in *Escherichia coli*: disulphide linkages are a structural component of prochymosin-containing inclusion bodies", J.M. Schoemaker et. al., The EMBO Journal, 1985, Vol. 4, No. 3, pp 775-780
27	"Recovery of soluble human renin from inclusion bodies produced in recombinant *Escherichia coli*", Satish K. Sharma, Journal of Biotechnology, 4 (1986) 119-124
28	"Isolation and purification of protein granules from *Escherichia coli* cells overproducing bovine growth hormone", Ronald G. Schoner et. al., Bio Technology, February 1985, pp 151-154
29	"Size and density of protein inclusion bodies", G. Taylor et. al., Bio/Technology, Vol 4, June 1986, pp 553-557
30	"Alteration of catalytic properties of chymosin by site-directed mutagenesis", Junko Suzuki et. al., Protein Engineering, Vol. 2, No. 7, pp 563-569, 1989
31	"Site-directed mutagenesis reveals functional contribution of Thr218, Lys220 and Asp304 in chymosin", Junko Suzuki et. al., Protein Engineering, Vol. 4, No. 1, pp 69-71, 1990

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

34	"Purification of recombinant salmon growth hormone expressed in Escherichia coli, Seiji Sugimoto, Biotechnology Letters, Vol. 13, No. 6, 389-394, (1991)
35	"Protein engineering to optimize recombinant protein purification", Mathias Uhlen et. al., Biochemical Society Transactions, Vol 16, pp 111-115, 1988
36	"Solubilization and activation of recombinant calf prochymosin from *Escherichia coli*", FIONA A. O. MARSTON, et al., 613th Meeting, Cardiff, Vol. 13, pg. 1035
37	"Sequencing of a cDNA encoding the human fast-twitch skeletal muscle isoform of troponin I", Lei Zhu et. al. Biochimica et Biophysica Acta 1217 (1994) 338-340
38	"Reconstitution of Lactic Dehydrogenase. Noncovalent Aggregation vs. Reactivation. 1. Physical Properties and Kinetics of Aggregation", Gerd Zettlmeissl et. al., Physical Properties of LDH Aggregates, Vol 18, No. 25, 1979, 5567-5571
39	"Increase of Solubility of Foreign Proteins in *Escherichia coli* by Coproduction of the Bacterial Thioredoxin", Takashi Yasukawa; The Journal of Biological Chemistry, Vol. 270, No. 43, October 27, 1995, pp 25328-25331
40	"Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases", Philip A. Walker et. al., Bio/Technology, Vol. 12, June 1994, pp 601-605
41	"Effects of Low Concentrations of Guanidine. HC1 on the Reconstitution of Lactic Dehydrogenase from Pig Muscle *in vitro* – Evidence for Guanidine Binding to the Native Enzyme", Gerd Zettlmeissl et. al., Eur. J.Biochem, 100, pp 593-598 (1979)
42	"High-level direct expression of semi-synthetic human interleukin-6 in *Escherichia coli* and production of n-terminus met-free product", Hisahi Yasueda et. al., Bio-Technology, Vol. 8, November 1990, pp 1036-1040

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

41	"Troponin I is present in human cartilage and inhibits angiogenesis", Marsha A. Moses et. al., Proc. Natl. Acad. Sci. USA, Vol. 96, pp 2645-2650, March 1999
42	"Structure, evolution, and regulation of a fast skeletal muscle troponin I gene", Albert S. Baldwin et. al., Proc. Natl. Acad. Sci. USA, Vol. 82, pp 8080-8084, December 1985
43	"Utilization of Zeolite Y in the removal of anionic, cationic and nonionic detergents during purification of proteins", Zoltan Blum et. al., Biotechnology Techniques, Vol 5, No. 1, pp 49-54, (1991)
44	"Principles that govern the folding of Protein Chains", Christian B. Anfinsen, SCIENCE, 20 July 1973, Volume 181, Number 4096, pp 223-230
45	"Overexpression of human cardiac troponin-I and troponin-C in *Escherichia coli* and their purification and characterization – Two point mutations allow high-level expression of troponin-I", Eman AL-HILLAWI et. al., Eur. J. Biochem., 225, pp 1195-1201, (1994)
46	"Recombinant protein expression in *Escherichia coli*", Francois Baneyx, Current Opinion in Biotechnology, 1999, Vol. 10, pp 411-421
47	"Structure and morphology of protein inclusion bodies in *Escherichia coli*", Gregory A. Bowden, Bio/Technology, Vol 9, August 1991, pp 725-730
48	"Renaturation, purification and characterization of recombinant F_{ab}-fragments produced in *Escherichia coil*", Johannes Buchner et. al., Bio/Technology, Vol. 9, February 1991, pp 157-162
49	"Stabilization of Protein Structure by Sugars", Tsutomu Arakawa et. al., Biochemistry, 1982, Vol. 21, pp 6536-6544
50	"Synthesis and cloning of a gene coding for a fusion protein containing mouse epidermal growth factor", G. Allen et.al., Journal of Biotechnology, Vol. 5, (1987) pp 93-114
51	"Denatured States of Proteins", Ken A. Dill, Annu. Rev. Biochem., 1991, Vol. 60, pp 795-825

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

52	"Choice of Cellular Protein Expression System", David Gray et. al., Current Protocols in Protein Science, (2000), pp 5.16.1-5.16.34
53	"Chromatofocusing", Alan Williams, Current Protocols in Protein Science, (1997), pp 8.5.1-8.5.10
54	"Overview of Protein Purification and Characterization", R.K. Scopes, Current Protocols in Protein Science, (1995), pp 1.1.1-1.1.5
55	"Strategies for Protein Purification", R.K. Scopes, Current Protocols in Protein Science, (1995), pp 1.2.1-1.3.7
56	"Conventional Chromatographic Separations", Ben. M. Dunn, Current Protocols in Protein Science, (1997), pp 8.0.1-8.1.9
57	"Dominant Forces in Protein Folding", Ken A. Dill, Biochemistry, Vol. 29, Number 31, August 7, 1990, pp 7133-7155
58	"Nativelike Secondary Structure in Interleukin-1ß Inclusion Bodies by Attenuated Total Reflectance FTIR", Keith Oberg et. al., Biochemistry, 1994, Vol. 33, pp 2628-2634
59	"Efficient rentaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in *Escherichia coli* as inclusion bodies", Gaetano Orsini et. al., Eur. J. Biochem, Vol. 195, pp 691-697 (1991)
60	"Culture of Yeast for the Production of Heterologous Proteins", Michael A. Romanos et. al., Current Protocols in Protein Science, (1995), pp 5.8.1-5.8.17
61	"Solubility as a function of protein structure and solvent components", Catherine H. Schein, Bio/Technology, Vol. 8, April 1990, pp 308-317

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

62	"Synthesis of calf prochymosin (prorennin) in *Escherichia coli*", J.S. Emtage, Proc. Natl. Acad. Sci. USA, Vol. 80, pp 3671-3675, June 1983
63	"High-Level Expression in *Escherichia coli* of Biologically Active Bovine Growth Hormone", Henry J. George et. al., DNA, Volume 4, Number 4, 1985, pp 273-281
64	"Purification of Recombinant Proteins", Paul T. Wingfield, Current Protocols in Protein Science, 1997, 6.0.1.-6.7.10
65	"Reconstitution of Lactic Dehydrogenase. Noncovalent Aggregation vs. Reactivation. 2. Reactivation of Irreversibly Denatured Aggregates", Rainer Rudolph et. al., Biochemistry, Vol 18, No. 25, 1979, pp 5572-5575
66	"Gene Expression in Recombinant *Escherichia coli*", Joan Stader, 1995, pp 1-51
67	"Gene Expression in Recombinant Bacillus", Matti Sarvas, Gene Expression in Recombinant Mocroorganisms, 1995, pp 55-120
68	"Use of Stabilizing Additives", Ciaran O'Fagain, Stabilizing Protein Function, 1997, pp 69-79
69	"Recombinant human insulin-like growth factor II expressed in *Escherichia coli*", Thomas C. Furman et. al., Bio/Technology, Vol. 5, October 1987, pp 1047-1051
70	"High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials", Arthur E. Frankel et. al., Protein Expression and Purification, 16, 190-201, (1999)

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

7	"Recovery of soluble, biologically active recombinant proteins from total bacterial lysates using ion exchange resin", Adolf Hoess et. al., Bio/Technology, Vol. 6, October 1998, pp 1214-1217
7	"Renaturation of Recombinant Proteins Produced as Inclusion Bodies", Bernhard E. Fischer, Biotech. Adv., Vol. 12, pp 89-101, 1994
7	"Refolding and crystallographic studies of eukaryotic proteins produced in *Escherichia coli*", Kiyoshi Nagai et. al., Biochemical Society Transactions, 1988, Vol. 16, pp 108-110
7	"Protein folding intermediates and inclusion body formation", Anna Mitraki et. al., Bio/Technology, Vol. 7, July 1989, pp 690-697
7	"Overview of Protein Expression in *Saccharomyces cerevisiae*", Robert L. Strausberg, Production of Recombinant Proteins, 1995, pp 5.6.1-5.6.7
7	"Production of recombinant proteins", Paul T. Wingfield, Current Protocols in Protein Science, Supplement 20, 2000, pp 5.0.1-5.16.25
7	"Fermentation and Growth of *Escherichia coli* for Optimal Protein Production", Alain Bernard et. al., Current Protocols in Protein Science, 1995, pp 5.3.1-5.3.18
7	"Protein Folding and its Implications for the Production of Recombinant Proteins", Roman Hlodan et. al., Biotechnology and Genetic Engineering Reviews, Vol. 9, December 1991, pp 47-88
7	"Reconstitution of Rabbit Skeletal Muscle Troponin from the Recombinant Subunits All Exressed in and Purified from E. coli, Setsuko Fujita-Becker et. al., J. Biochem., 114, 438-444, (1993)
8	"A novel sequential procedure to enhance the renaturation of recombinant protein from *Escherichia coli* inclusion bodies", Bernhard Fischer et. al., Protein Engineering, Vol. 5, No. 6, pp 593-596, 1992

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

81	"Optimized procedures for purification and solubilization of basic fibroblast growth factor inclusion bodies", D. Estape et. al., Biotechnology Techniques, Vol. 10, No. 7, July 1996, p 481-484
82	"The Use of Zeolite Y in the Purification of Intra Cellular Accumulated Proteins from Genetically Engineered Cells, Hakan Eriksson et. al., Biotechnology Techniques, 1992, pp 239-244
83	"Convenient and Efficient *In Vitro* Folding of Disulfide-Containing Globular Protein from Crude Bacterial Inclusion Bodies", Junichiro Futami et. al., J. Biochem., Vol. 127, pp 435-444 (2000)
84	"Enzyme Applications", M.D. Trevan et. al., Biotechnology: The Biological Principles, 1987, pp 203-210
85	"Comparing the Refolding and Reoxidation of Recombinant Porcine Growth Hormone from a Urea Denatured State and from *Escheria coli* Inclusion Bodies", Michael Cardamone et. al., Biochemistry 1995, Vol. 34, pp 5773-5794
86	"The use of EDTA or Polymyxin with Lysonzyme for the Recovery of Intracellular Products from *Escherichia coli*", C.R. Dean et. al., Biotechnology Techniques, Volume 6, No. 2 March/April 1992 pp 133-138
87 *	"Serodiagnosis of Antibodies to the Human AIDS Retrovirus with a Bacterially Synthesized *ENV* Polypeptide", Cirilo D. Cabradilla, Bio/Technology, Vol. 4, February 1986, pp 128-133
88	"Aggregation and Denaturation of Apomyoglobin in Aqueous Urea Solutions", Linda R. De Young et. al., Biochemistry, 1993, 32, 3877-3886
89	"Refolding of recombinant proteins", Eliana De Bernadez Clark, Biochemical Engineering, 1998, 9, 157-163
90	"Pharmacoeconomics", Joseph F. Heyse et. al., Encyclopedia of Biopharmceutical Statistics, 2000, pp 387-401
91	"Recombinant DNA Proteins and Drug Discovery", Christopher Hentschel, Genetically Engineered Human Therapeutic Drugs, 1988, pp 3-6
92	"Chapter 8. Bioproducts and Economics", Harvey W. Blanch et. al., Biochemical Engineering, 1996, pp 609-671

Examiner:	Date:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 22918/1	SERIAL NO. 10/080,919
	APPLICANT(S): **Lucia Irene Gonzalez-Villasenor**	
	FILING DATE: **February 22, 2002**	ART UNIT:

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

93	"Solubilization of Protein Aggregates", Fiona A. O. Marston et. al., Methods in Enzymology, Vol. 182, pp 264-276, 1990
94	"Development of an Intravenous γ-Globulin with Fc Activities", Y Masuho et. al, Vox Sang. 32: p 175-181 (1977)
95	"Reversible protection of disulfide bonds followed by oxidative folding render recombinant hCGß highly immunogenic", Asok Mukhopadhyay, Vaccine, 18 (2000) 1802-1810
96	"Refolding of Therapeutic Proteins Produced in *Escherichia coli* as Inclusion Bodies", Satoru Misawa et. al., Biopolymers, 51, 297-307, (1999)
97	"Global Suppression of Protein Folding Defects and Inclusion Body Formation", Anna Mitraki et. al., Science, Vol. 253, pp 54-58
98	"Structural characterization of the human fast skeletal muscle troponin I gene (TNN12)", Antony J. Mullen et. al., GENE, 242, (2000) 313-320

Examiner:	Date: